Decision Resources, Inc., announces the publication of Psoriasis and Associated Arthropathy, a new study that evaluates the therapeutic and commercial potential of emerging biologic therapies for psoriasis and psoriatic arthritis (PsA) over a 2000-2010 forecast period. Psoriasis affects more than 10 million people in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). PsA affects an estimated 20% of people with psoriasis.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

Launches of new biologic drugs are expected to satisfy important unmet needs in psoriasis treatment-particularly the need for effective treatment for moderate-to-severe cases. We estimate that sales of biologic agents for the treatment of psoriasis will generate more than $373 million in 2005 and approximately $923 million in 2010 in the major markets. The market impact of the new biologics will be greatest in the United States.

Competition in the psoriasis market pits two classes of biologic drugs now in late-stage development-cell-adhesion molecule (CAM) antagonists and tumor necrosis factor (TNF) inhibitors-against each other. Two CAM antagonists are racing to be the first in the class to reach the market for psoriasis, alafacept (Biogen's Amevive) and hu1124 (Genentech/Xoma's Xanelim). These agents are expected to be launched by early 2003, and could potentially become the most commercially successful new drugs for psoriasis during our forecast period.

TNF inhibitors are expected to quickly emerge as the principal drivers of growth in the PsA market, prescribed mainly by rheumatologists. Furthermore, because PsA represents a significant segment of the psoriasis population, we believe that the usage of TNF inhibitors in PsA will facilitate their acceptance by the dermatologist community in the care of the general psoriasis population.

Psoriasis and Associated Arthropathy offers invaluable market intelligence for companies developing drugs to treat these indications. This study is part of the Immune and Inflammatory Disorders portfolio, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.

Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or sama@dresources.com (e-mail). In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or fbidart@decisionresources.be (e-mail). In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp (e-mail).

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X78486513

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION

AP Archive: http://photoarchive.ap.org/

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., 781-296-2553,
sama@dresources.com

Cardiovascular Complications of Diabetes, a New Decision Resources Study, Identifies Market Opportunities for Therapies That Address the Unique Treatment Concerns of Type 2 Diabetics With Cardiovascular Risk Factors

View Now